Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of Prematurity [Biochemistry and Molecular Biology]

Conclusions. Clearance of bevacizumab from the bloodstream in premature infants takes at least 2 months. Although serum free VEGF levels decreased following either laser or bevacizumab treatment, the reductions were more significant in the IVB-treated groups. Potential long-term effects of systemic exposure to bevacizumab in infants need to be studied further.

http://www.iovs.org/cgi/content/full/56/2/956?rss=1

Source: Investigative Ophthalmology - February 9, 2015 Category: Opthalmology Authors: Kong, L., Bhatt, A. R., Demny, A. B., Coats, D. K., Li, A., Rahman, E. Z., Smith, O. E., Steinkuller, P. G. Tags: Biochemistry and Molecular Biology Source Type: research